Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1101966

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1101966

Europe Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 129 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Europe Peptide Therapeutics Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).

Peptide medications have so many desired qualities, they are transitory in the body due to quick degradation and clearance. Many approaches have been used to boost the stability of peptide therapeutics. Some peptides and proteins have half-lives of only a few minutes, making them inefficient for medication delivery. Peripheral blood-mediated proteolysis, real and hepatic evacuation, and receptor-mediated endocytosis are all mechanisms implicated in their clearance. The molecular weight of the substance is one of the key reasons for its quick clearance.

In Europe, cardiovascular diseases (CVD) continue to be the primary cause of death, accounting for 45% of all deaths in the region, according to the National Library of Medicines. Every year, more than 4 million Europeans die from cardiovascular disease (CVD), mostly coronary heart disease (CHD) and stroke. Many more are admitted to hospitals, and several others acquire long-term disabilities that necessitate lifetime therapies. CVD has huge economic ramifications for Europe, in addition to human misery. CVD is predicted to cost the EU economy €210 billion per year, which includes direct healthcare expenses as well as non-health expenditures such as lost productivity and informal care for people with CVD. The cardiovascular disease mortality rate in Central and Eastern Europe (CEE/CIS) is the highest in the world.

CVD death rates are greater in CEE and CIS, and they occur at younger ages as well. Premature CVD mortality among men in Russia and Belarus (65 years) is more than ten times greater than in Switzerland (300 vs. 26 per 100 000, respectively). Men aged 55-59 years in various CIS nations (Belarus, Kazakhstan, Kyrgyzstan, Russia, and Ukraine) have a higher CVD death rate than men aged 75-79 years in France. When comparing CEE to other European countries, women's premature death patterns are similar to men's, however at lower rates. The requirement for an effective treatment approach for these disorders is at its peak in the region. The adoption of peptide therapeutics is estimated to surge due to this.

The Germany market dominated the Europe Peptide Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,458.3 million by 2028. The UK market is estimated to grow at a CAGR of 4.7% during (2022 - 2028). Additionally, The France market would witness a CAGR of 6.3% during (2022 - 2028).

Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Innovative
  • Generic

By Route of Administration

  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others

By Synthesis Technology

  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology

By Type of Manufacturers

  • In-house
  • Outsourced

By Application

  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled

  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.1 Objectives
  • 1.2 Market Scope
  • 1.3 Segmentation
    • 1.3.1 Europe Peptide Therapeutics Market, by Type
    • 1.3.2 Europe Peptide Therapeutics Market, by Route of Administration
    • 1.3.3 Europe Peptide Therapeutics Market, by Synthesis Technology
    • 1.3.4 Europe Peptide Therapeutics Market, by Type of Manufacturers
    • 1.3.5 Europe Peptide Therapeutics Market, by Application
    • 1.3.6 Europe Peptide Therapeutics Market, by Country
  • 1.4 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Approvals and Trails
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)

Chapter 4. Europe Peptide Therapeutics Market by Type

  • 4.1 Europe Innovative Market by Country
  • 4.2 Europe Generic Market by Country

Chapter 5. Europe Peptide Therapeutics Market by Route of Administration

  • 5.1 Europe Parenteral Route Market by Country
  • 5.2 Europe Pulmonary Market by Country
  • 5.3 Europe Mucosal Market by Country
  • 5.4 Europe Oral Route Market by Country
  • 5.5 Europe Others Market by Country

Chapter 6. Europe Peptide Therapeutics Market by Synthesis Technology

  • 6.1 Europe Liquid Phase Peptide Synthesis (LPPS) Market by Country
  • 6.2 Europe Solid Phase Peptide Synthesis (SPPS) Market by Country
  • 6.3 Europe Hybrid Technology Market by Country

Chapter 7. Europe Peptide Therapeutics Market by Type of Manufacturers

  • 7.1 Europe In-house Market by Country
  • 7.2 Europe Outsourced Market by Country

Chapter 8. Europe Peptide Therapeutics Market by Application

  • 8.1 Europe Metabolic Market by Country
  • 8.2 Europe Cardiovascular Disorder Market by Country
  • 8.3 Europe GIT & Renal Market by Country
  • 8.4 Europe Antiinfection & Dermatology Market by Country
  • 8.5 Europe Respiratory Market by Country
  • 8.6 Europe Central Nervous System Market by Country
  • 8.7 Europe Cancer Market by Country
  • 8.8 Europe Pain Market by Country
  • 8.9 Europe Others Market by Country

Chapter 9. Europe Peptide Therapeutics Market by Country

  • 9.1 Germany Peptide Therapeutics Market
    • 9.1.1 Germany Peptide Therapeutics Market by Type
    • 9.1.2 Germany Peptide Therapeutics Market by Route of Administration
    • 9.1.3 Germany Peptide Therapeutics Market by Synthesis Technology
    • 9.1.4 Germany Peptide Therapeutics Market by Type of Manufacturers
    • 9.1.5 Germany Peptide Therapeutics Market by Application
  • 9.2 UK Peptide Therapeutics Market
    • 9.2.1 UK Peptide Therapeutics Market by Type
    • 9.2.2 UK Peptide Therapeutics Market by Route of Administration
    • 9.2.3 UK Peptide Therapeutics Market by Synthesis Technology
    • 9.2.4 UK Peptide Therapeutics Market by Type of Manufacturers
    • 9.2.5 UK Peptide Therapeutics Market by Application
  • 9.3 France Peptide Therapeutics Market
    • 9.3.1 France Peptide Therapeutics Market by Type
    • 9.3.2 France Peptide Therapeutics Market by Route of Administration
    • 9.3.3 France Peptide Therapeutics Market by Synthesis Technology
    • 9.3.4 France Peptide Therapeutics Market by Type of Manufacturers
    • 9.3.5 France Peptide Therapeutics Market by Application
  • 9.4 Russia Peptide Therapeutics Market
    • 9.4.1 Russia Peptide Therapeutics Market by Type
    • 9.4.2 Russia Peptide Therapeutics Market by Route of Administration
    • 9.4.3 Russia Peptide Therapeutics Market by Synthesis Technology
    • 9.4.4 Russia Peptide Therapeutics Market by Type of Manufacturers
    • 9.4.5 Russia Peptide Therapeutics Market by Application
  • 9.5 Spain Peptide Therapeutics Market
    • 9.5.1 Spain Peptide Therapeutics Market by Type
    • 9.5.2 Spain Peptide Therapeutics Market by Route of Administration
    • 9.5.3 Spain Peptide Therapeutics Market by Synthesis Technology
    • 9.5.4 Spain Peptide Therapeutics Market by Type of Manufacturers
    • 9.5.5 Spain Peptide Therapeutics Market by Application
  • 9.6 Italy Peptide Therapeutics Market
    • 9.6.1 Italy Peptide Therapeutics Market by Type
    • 9.6.2 Italy Peptide Therapeutics Market by Route of Administration
    • 9.6.3 Italy Peptide Therapeutics Market by Synthesis Technology
    • 9.6.4 Italy Peptide Therapeutics Market by Type of Manufacturers
    • 9.6.5 Italy Peptide Therapeutics Market by Application
  • 9.7 Rest of Europe Peptide Therapeutics Market
    • 9.7.1 Rest of Europe Peptide Therapeutics Market by Type
    • 9.7.2 Rest of Europe Peptide Therapeutics Market by Route of Administration
    • 9.7.3 Rest of Europe Peptide Therapeutics Market by Synthesis Technology
    • 9.7.4 Rest of Europe Peptide Therapeutics Market by Type of Manufacturers
    • 9.7.5 Rest of Europe Peptide Therapeutics Market by Application

Chapter 10. Company Profiles

  • 10.1 Eli Lilly And Company
    • 10.1.1 Company Overview
    • 10.1.2 Financial Analysis
    • 10.1.3 Regional Analysis
    • 10.1.4 Research & Development Expenses
    • 10.1.5 Recent strategies and developments:
      • 10.1.5.1 Partnerships, Collaborations, and Agreements:
      • 10.1.5.2 Acquisition and Mergers:
      • 10.1.5.3 Approvals and Trails:
  • 10.2 AstraZeneca PLC
    • 10.2.1 Company Overview
    • 10.2.2 Financial Analysis
    • 10.2.3 Regional Analysis
    • 10.2.4 Research & Development Expenses
    • 10.2.5 Recent strategies and developments:
      • 10.2.5.1 Partnerships, Collaborations, and Agreements:
      • 10.2.5.2 Acquisition and Mergers:
  • 10.3 Teva Pharmaceutical Industries Ltd.
    • 10.3.1 Company Overview
    • 10.3.2 Financial Analysis
    • 10.3.3 Regional Analysis
    • 10.3.4 Research & Development Expenses
    • 10.3.5 Recent strategies and developments:
      • 10.3.5.1 Product Launches and Product Expansions:
      • 10.3.5.2 Approvals and Acquisitions:
  • 10.4 Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Financial Analysis
    • 10.4.3 Segmental and Regional Analysis
    • 10.4.4 Research & Development Expense
    • 10.4.5 Recent strategies and developments:
      • 10.4.5.1 Acquisition and Mergers:
      • 10.4.5.2 Approvals and Trails:
  • 10.5 Pfizer, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Analysis
    • 10.5.3 Regional & Segmental Analysis
    • 10.5.4 Research & Development Expense
    • 10.5.5 Recent strategies and developments:
      • 10.5.5.1 Acquisition and Mergers:
  • 10.6 Sanofi S.A.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Analysis
    • 10.6.3 Segmental and Regional Analysis
    • 10.6.4 Research & Development Expense
    • 10.6.5 Recent strategies and developments:
      • 10.6.5.1 Partnerships, Collaborations, and Agreements:
  • 10.7 GlaxoSmithKline PLC
    • 10.7.1 Company Overview
    • 10.7.2 Financial Analysis
    • 10.7.3 Segmental and Regional Analysis
    • 10.7.4 Research & Development Expense
  • 10.8 Takeda Pharmaceutical Company Limited
    • 10.8.1 Company Overview
    • 10.8.2 Financial Analysis
    • 10.8.3 Regional Analysis
    • 10.8.4 Research & Development Expense
    • 10.8.5 Recent strategies and developments:
      • 10.8.5.1 Partnerships, Collaborations, and Agreements:
      • 10.8.5.2 Approvals and Trails:
  • 10.9 Lonza Group AG
    • 10.9.1 Company Overview
    • 10.9.2 Financial Analysis
    • 10.9.3 Segmental and Regional Analysis
    • 10.9.4 Research & Development Expenses
  • 10.10. Amgen, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Financial Analysis
    • 10.10.3 Regional Analysis
    • 10.10.4 Research & Development Expenses
    • 10.10.5 Recent strategies and developments:
      • 10.10.5.1 Partnerships, Collaborations, and Agreements:

LIST OF TABLES

  • TABLE 1 Europe Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 2 Europe Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Peptide Therapeutics Market
  • TABLE 4 Acquisition and Mergers- Peptide Therapeutics Market
  • TABLE 5 Approvals and trails- Peptide Therapeutics Market
  • TABLE 6 Europe Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 7 Europe Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 8 Europe Innovative Market by Country, 2018 - 2021, USD Million
  • TABLE 9 Europe Innovative Market by Country, 2022 - 2028, USD Million
  • TABLE 10 Europe Generic Market by Country, 2018 - 2021, USD Million
  • TABLE 11 Europe Generic Market by Country, 2022 - 2028, USD Million
  • TABLE 12 Europe Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 13 Europe Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 14 Europe Parenteral Route Market by Country, 2018 - 2021, USD Million
  • TABLE 15 Europe Parenteral Route Market by Country, 2022 - 2028, USD Million
  • TABLE 16 Europe Pulmonary Market by Country, 2018 - 2021, USD Million
  • TABLE 17 Europe Pulmonary Market by Country, 2022 - 2028, USD Million
  • TABLE 18 Europe Mucosal Market by Country, 2018 - 2021, USD Million
  • TABLE 19 Europe Mucosal Market by Country, 2022 - 2028, USD Million
  • TABLE 20 Europe Oral Route Market by Country, 2018 - 2021, USD Million
  • TABLE 21 Europe Oral Route Market by Country, 2022 - 2028, USD Million
  • TABLE 22 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 23 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 24 Europe Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 25 Europe Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 26 Europe Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2018 - 2021, USD Million
  • TABLE 27 Europe Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2022 - 2028, USD Million
  • TABLE 28 Europe Solid Phase Peptide Synthesis (SPPS) Market by Country, 2018 - 2021, USD Million
  • TABLE 29 Europe Solid Phase Peptide Synthesis (SPPS) Market by Country, 2022 - 2028, USD Million
  • TABLE 30 Europe Hybrid Technology Market by Country, 2018 - 2021, USD Million
  • TABLE 31 Europe Hybrid Technology Market by Country, 2022 - 2028, USD Million
  • TABLE 32 Europe Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 33 Europe Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 34 Europe In-house Market by Country, 2018 - 2021, USD Million
  • TABLE 35 Europe In-house Market by Country, 2022 - 2028, USD Million
  • TABLE 36 Europe Outsourced Market by Country, 2018 - 2021, USD Million
  • TABLE 37 Europe Outsourced Market by Country, 2022 - 2028, USD Million
  • TABLE 38 Europe Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 39 Europe Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 40 Europe Metabolic Market by Country, 2018 - 2021, USD Million
  • TABLE 41 Europe Metabolic Market by Country, 2022 - 2028, USD Million
  • TABLE 42 Europe Cardiovascular Disorder Market by Country, 2018 - 2021, USD Million
  • TABLE 43 Europe Cardiovascular Disorder Market by Country, 2022 - 2028, USD Million
  • TABLE 44 Europe GIT & Renal Market by Country, 2018 - 2021, USD Million
  • TABLE 45 Europe GIT & Renal Market by Country, 2022 - 2028, USD Million
  • TABLE 46 Europe Antiinfection & Dermatology Market by Country, 2018 - 2021, USD Million
  • TABLE 47 Europe Antiinfection & Dermatology Market by Country, 2022 - 2028, USD Million
  • TABLE 48 Europe Respiratory Market by Country, 2018 - 2021, USD Million
  • TABLE 49 Europe Respiratory Market by Country, 2022 - 2028, USD Million
  • TABLE 50 Europe Central Nervous System Market by Country, 2018 - 2021, USD Million
  • TABLE 51 Europe Central Nervous System Market by Country, 2022 - 2028, USD Million
  • TABLE 52 Europe Cancer Market by Country, 2018 - 2021, USD Million
  • TABLE 53 Europe Cancer Market by Country, 2022 - 2028, USD Million
  • TABLE 54 Europe Pain Market by Country, 2018 - 2021, USD Million
  • TABLE 55 Europe Pain Market by Country, 2022 - 2028, USD Million
  • TABLE 56 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 57 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 58 Europe Peptide Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 59 Europe Peptide Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 60 Germany Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 61 Germany Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 62 Germany Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 63 Germany Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 64 Germany Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 65 Germany Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 66 Germany Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 67 Germany Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 68 Germany Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 69 Germany Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 70 Germany Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 71 Germany Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 72 UK Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 73 UK Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 74 UK Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 75 UK Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 76 UK Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 77 UK Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 78 UK Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 79 UK Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 80 UK Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 81 UK Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 82 UK Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 83 UK Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 84 France Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 85 France Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 86 France Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 87 France Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 88 France Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 89 France Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 90 France Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 91 France Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 92 France Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 93 France Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 94 France Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 95 France Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 96 Russia Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 97 Russia Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 98 Russia Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 99 Russia Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 100 Russia Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 101 Russia Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 102 Russia Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 103 Russia Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 104 Russia Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 105 Russia Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 106 Russia Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 107 Russia Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 108 Spain Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 109 Spain Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 110 Spain Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 111 Spain Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 112 Spain Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 113 Spain Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 114 Spain Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 115 Spain Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 116 Spain Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 117 Spain Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 118 Spain Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 119 Spain Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 120 Italy Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 121 Italy Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 122 Italy Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 123 Italy Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 124 Italy Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 125 Italy Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 126 Italy Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 127 Italy Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 128 Italy Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 129 Italy Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 130 Italy Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 131 Italy Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 132 Rest of Europe Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 133 Rest of Europe Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 134 Rest of Europe Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 135 Rest of Europe Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 136 Rest of Europe Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 137 Rest of Europe Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 138 Rest of Europe Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 139 Rest of Europe Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 140 Rest of Europe Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 141 Rest of Europe Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 142 Rest of Europe Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 143 Rest of Europe Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 144 Key Information - Eli Lilly And Company
  • TABLE 145 KEY INFORMATION - ASTRAZENECA PLC
  • TABLE 146 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 147 Key Information - Novartis AG
  • TABLE 148 Key Information - Pfizer, Inc.
  • TABLE 149 Key Information - Sanofi S.A.
  • TABLE 150 Key Information - GlaxoSmithKline PLC
  • TABLE 151 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 152 Key Information - Lonza Group AG
  • TABLE 153 Key Information - Amgen, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Recent strategies and developments: Eli Lilly And Company
  • FIG 5 Recent strategies and developments: AstraZeneca PLC
  • FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
  • FIG 7 Recent strategies and developments: Novartis AG
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!